What this means
A trial plans to compare tocotrienol capsules with placebo pills for six months. It has not reported results, so it cannot yet show whether the supplement helps or is safe.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 35–50
- Where
- 1 site
The science
- Registered title
- Tocotrienol Supplementa as A Senolytic Agent in Middle-aged Adults
- Trial ID
- NCT07637487 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Healthy
- What is tested
- Treatment, Placebo
- Sponsor
- National University of Malaysia
- Ages
- 35 Years to 50 Years
- Dates
- First posted Jun 9, 2026 · updated Jun 9, 2026
Registry summary
The goal of this clinical trial is to determine whether tocotrienol works as a senolytic agent to delay age-related biological changes in middle-aged adults. The study will also evaluate the safety of tocotrienol supplementation. The main questions it aims to answer are:
Does tocotrienol reduce markers of cellular senescence, inflammation, oxidative stress, and mitochondrial dysfunction?
What health changes or medical issues occur in participants taking tocotrienol?
Researchers will compare tocotrienol-rich fraction to a placebo (a look-alike capsule with no active ingredient) to determine whether tocotrienol is effective in modulating aging-related pathways.
Participants will:
Take tocotrienol (200 mg/day) or a placebo daily for 6 months
Attend study visits at baseline, 3 months, and 6 months for clinical assessments and laboratory tests
Undergo blood sampling and health evaluations, including measures of senescence-associated secretory phenotype (SASP), inflammation, oxidative stress, mitochondrial function, vascular health, skin status, cognitive function, body composition, and bone mineral density.
Complete questionnaires related to diet throughout the study period
This study aims to provide clinical evidence on the potential of tocotrienol as a senolytic intervention for promoting healthy aging and reducing the risk of age-related diseases.
Sites (1)
- National University of Malaysia, Kuala Lumpur, Kuala Lumpur, Malaysia